US Patent Issued to Newsoara Biopharmaceutical Technology (Suzhou) on Sept. 1 for "TL1A-binding molecules, IL-23p19-binding molecules, and bispecific antigen-binding molecules, and uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,723,093, issued on Sept. 1, was assigned to Newsoara Biopharmaceutical Technology (Suzhou) Co. Ltd. (JiangSu, China).

"TL1A-binding molecules, IL-23p19-binding molecules, and bispecific antigen-binding molecules, and uses thereof" was invented by Wenyi Wang (JiangSu Province, China), Qingqing Yin (JiangSu Province, China) and Yuannian Li (JiangSu Province, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to TL1A-binding molecules, IL-23p19-binding molecules, and bispecific antigen-binding molecules that simultaneously target TL1A and IL-23p19. The disclosure also relates to nucleic acid molecules encoding said antigen-...